Company profile
REDHILL BIOPHARMA LTD.
NASDAQ:RDHLBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| OPAGANIB | phase2_3 | — | 4 | completed, terminated, withdrawn |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (18)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03377179 | phase2 | completed | 2018-03-07 | 2022-06-21 | RedHill Biopharma Limited | A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma |
| NCT04414618 | phase2 | completed | 2020-07-02 | 2020-11-26 | RedHill Biopharma Limited | A Study of Opaganib in Coronavirus Disease 2019 Pneumonia |
| NCT02757326 | phase1_2 | terminated | 2016-12-13 | 2019-05-01 | RedHill Biopharma Limited | ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma |
| NCT01488513 | phase1 | completed | 2011-08-01 | 2014-08-01 | RedHill Biopharma Limited | ABC294640 in Treating Patients With Advanced Solid Tumors |
| NCT02246439 | phase3 | completed | 2014-12-08 | 2017-02-13 | RedHill Biopharma Limited | BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis |
FDA applications (0)
No records yet.